There are four combination strategies approved by the FDA: two for kidney cancer [pembrolizumab (PD-1 antibody) plus axitinib (VEGFR/PDGFR inhibitor), and avelumab (PD-L1 antibody) plus axitinib], one for endometrial carcinoma [pembrolizumab plus lenvatinib (VEGFR/FGFR inhibitor)] and one for NSCLC (atezolizumab, bevacizumab, and chemotherapy) (57). Here, KDR is linked to non-small cell lung carcinoma.